[Attention-getting cross infections: Extended-spectrum beta-lactamase-producing bacterial infections].
Yoshida
Atsushi
A
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology; D011511:Proteus / Q000187:drug effects / Q000201:enzymology; D011512:Proteus Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D001618:beta-Lactamases / Q000096:biosynthesis*; D047090:beta-Lactams / Q000378:metabolism / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D047090:beta-Lactams; D001618:beta-Lactamases